German Appeals Court Overturns Keytruda SC Injunction; Halozyme Shares Slip
HALO sits 51% above its 52-week low of $61.225 on light trading volume (0.1× avg).
Summary
A higher regional court in Germany overturned the Munich preliminary injunction that had barred Merck from distributing and offering subcutaneous Keytruda in Germany — the injunction Halozyme won in December and highlighted in October as a major European win. Halozyme shares fell on the news. The company disagrees and says it will immediately file an infringement lawsuit in Germany seeking permanent relief, which it argues today's decision does not preclude. The dispute centers on European patent EP 2,797,622, which Merck is challenging in multiple suits across the U.S. and Europe. This removes, at least for now, the German barrier to Merck's SC Keytruda launch and weakens the leverage Halozyme held in the patent fight; the permanent-relief suit is the next step, with no date disclosed.
At the time of this announcement, HALO was trading at $92.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6B. The 52-week trading range was $61.23 to $134.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.